BTIG initiates coverage of ORIC Pharmaceuticals with Buy rating, $26 price target

BTIG initiated coverage on ORIC Pharmaceuticals's stock with a rating of Buy and a price target of $26.00.The price target implies an upside of 92.6% from the Sep 22 close of $13.50.Key takeaways from the analyst noteStrong Pipeline of Innovative Therapies: ORIC Pharmaceuticals has a promising pipe…